EAU 2014 - Poster: A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC)

STOCKHOLM, SWEDEN (UroToday.com) - Presented by D Petrylak,1 D Smith,2 L Appleman,3 M Fleming,4 A Hussain,5 R Dreicer,6 AO Sartor,7 N Shore,8 NJ Vogelzang,9 H Youssoufian,10 VA DiPippo,10 N Stambler,10 K Huang,10 RJ Israel10 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

Petrylak poster EAU 2014 thumb

 

1Yale University, New Haven, CT; 2University of Michigan, Ann Arbor, MI; 3University of Pittsburgh, Pittsburgh, PA; 4Virginia Oncology Associates, Norfolk, VA; 5University of Maryland, Baltimore, MD; 6Cleveland Clinic, Cleveland, OH; 7Tulane University, New Orleans, LA; 8Carolina Urologic Research Center, Myrtle Beach, SC; 9Comprehensive Cancer Centers of Nevada, Las Vegas, NV; 10Progenics Pharmaceuticals, Inc., Tarrytown, NY

 

Click HERE to listen to Daniel P. Petrylak, MD discuss the key points from this poster

 

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Winter Meeting / February 25-29 / Scottsdale, AZ
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Congress / October 17 - October 20 / Athens, Greece
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland
  • 2019 Think Tank / August 8-10 / Washington, DC
  • 2019 Annual Meeting / May 31 - June 6 / Chicago, IL
  • 2019 Annual Meeting / May 3-6 / Chicago, IL